Stocks Health care MDGL
NASDAQ · Health careMadrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. brought in $1.4B of revenue over the twelve months to September 30, 2026, up 92.8% from a year earlier. It posted a net loss of $155.5M. In fiscal 2025 capital spending exceeded operating cash flow by $190M. At September 30, 2026 it held $514.6M in cash against $341.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Madrigal Pharmaceuticals, Inc.
- Net worth
- Madrigal Pharmaceuticals, Inc. has a market value (market cap) of $10B at the latest share price, and shareholders' equity of $626.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $958.4M (+432.1% year on year), with a net loss of $288.3M. Over the 12 months to September 30, 2026: revenue $1.4B, net loss $155.5M.
- Cash flow
- In fiscal 2025 operations used $189.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Madrigal Pharmaceuticals, Inc.'s next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Madrigal Pharmaceuticals, Inc. does
Madrigal Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MDGL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $958.4M | -$288.3M | -$12.85 | -$190M |
| 2024 | $180.1M | -$465.9M | -$21.90 | -$457M |
| 2023 | $0 | -$373.6M | -$19.99 | -$325.7M |
| 2022 | $0 | -$295.4M | -$17.23 | -$225.1M |
| 2021 | $0 | -$241.8M | -$14.63 | -$184.1M |
| 2020 | $0 | -$202.2M | -$13.09 | -$157.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MDGL ranks in Health care
Latest SEC filings
What Madrigal Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Activist stake changed SCHEDULE 13D/A
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 50% to $431.3M versus the same quarter last year; diluted EPS $1.83 versus -$4.01.
- November 3, 2026
- August 12, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 71% to $364.3M versus the same quarter last year; diluted EPS -$1.99 versus -$1.50.
- July 30, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026
- June 17, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Madrigal Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $35M and sold $7M worth of shares in the last 90 days. Most of the selling (95%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Baker Bros. Advisors LPDirector | Boughtindirect | 60,400 | $23.1M |
| November 6, 2026 | Baker Bros. Advisors LPDirector | Boughtindirect | 13,740 | $5.3M |
| November 6, 2026 | Baker Bros. Advisors LPDirector | Boughtindirect | 2,000 | $793.2K |
| November 6, 2026 | Kelley Shannon TGeneral Counsel | Soldpre-planned (10b5-1) | 1,077 | $430.8K |
| November 4, 2026 | Baker Bros. Advisors LPDirector | Boughtindirect | 5,586 | $2.1M |
| November 4, 2026 | Baker Bros. Advisors LPDirector | Boughtindirect | 10,080 | $3.7M |
| September 11, 2026 | Sibold William JohnPresident and CEO, Director | Soldpre-planned (10b5-1) | 60 | $32K |
| September 11, 2026 | Sibold William JohnPresident and CEO, Director | Soldpre-planned (10b5-1) | 106 | $56.6K |
Who owns MDGL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 9.99% | November 6, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 9.2% | November 14, 2024 |
| Janus Henderson Group PLC13G, passive | 8.8% | May 15, 2026 |
| Paul A Friedman, M.D.13D, may seek influence | 7.8% | December 12, 2025 |
| Rebecca Taub, M.D.13D, may seek influence | 7.8% | December 12, 2025 |
| Paulson & Co. Inc.13G, passive | 6.1% | May 15, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 2,955,388 shares in total, about $1.28B at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector | 2,040,6822,040,682 held indirectly |
| Taub RebeccaDirector | 452,667 |
| Sibold William JohnPresident and CEO, Director | 197,746 |
| Friedman Paul ADirector | 187,164 |
| Levy Richard SDirector | 22,469 |
| Huntsman CaroleChief Commercial Officer | 12,692 |
| Dier MardiEVP and CFO | 12,490 |
| Kelley Shannon TGeneral Counsel | 10,397 |
| Soergel DavidChief Medical Officer | 10,033 |
| Daly James MDirector | 3,081 |
Questions about MDGL
What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as MDGL. Its shares trade on NASDAQ under the ticker MDGL.
What is Madrigal Pharmaceuticals, Inc.'s net worth?
Madrigal Pharmaceuticals, Inc. has a market value (market cap) of $10B at the latest share price, and shareholders' equity of $626.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Madrigal Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $155.5M on revenue of $1.4B.
How much revenue does Madrigal Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Madrigal Pharmaceuticals, Inc. reported revenue of $1.4B. That is 92.8% more than a year earlier.
When did Madrigal Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the activist stake changed from November 6, 2026.
When is Madrigal Pharmaceuticals, Inc.'s next earnings report?
Madrigal Pharmaceuticals, Inc.'s next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MDGL with
Follow MDGL
Get an email when Madrigal Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Madrigal Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.